24/7 Market News Snapshot 15 January, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

January 15, 2025

DENVER, Colo., 15 January, 2025 (247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp (NASDAQ:SLXN) is garnering significant attention in the market today, with its shares opening at $1.78 and soaring to $2.598, reflecting an impressive increase of approximately 46.78%. This substantial rise indicates heightened investor interest and enthusiasm about the company’s promising future. The current trading volume has reached 2.20 million shares, underlining a strong bullish sentiment among traders as SLXN continues to develop groundbreaking therapeutic solutions.

At the forefront of Silexion’s advancements is its innovative approach to combat KRAS-driven cancers, particularly through its proprietary second-generation small interfering RNA (siRNA) candidate, SIL-204. Recent preclinical studies have unveiled compelling results demonstrating that SIL-204 exhibits remarkable synergy when combined with established chemotherapy agents, such as 5-fluorouracil and irinotecan, which are commonly utilized in the treatment of pancreatic cancer. The research revealed that this combination significantly reduces cancer cell proliferation in human pancreatic tumor cell lines harboring the KRAS G12D mutation—one of the most predominant mutations associated with pancreatic cancer—much more effectively than chemotherapy alone.

Moreover, SIL-204 demonstrates potential synergy with gemcitabine, another critical drug in pancreatic cancer treatment, suggesting a capacity to enhance traditional therapeutic regimens. These promising results build on the previous success of Silexion’s first-generation product, LODER™ (siG12DLoder), which notably improved overall survival rates in Phase 2 trials when paired with chemotherapy.

Ilan Hadar, Chairman and CEO of Silexion, emphasized the significance of these discoveries, indicating that they could play a transformative role in treating pancreatic and other KRAS-mutated cancers. Silexion’s dedication to advancing RNA interference therapies positions the company strategically for future developments, including the imminent initiation of toxicology studies for SIL-204 and planning for Phase 2/3 clinical trials in the first half of 2026.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.